Affimed N.V. (AFMD)
NASDAQ: AFMD
· Real-Time Price · USD
0.18
-0.00 (-0.83%)
At close: May 19, 2025, 3:59 PM
-0.83% (1D)
| Bid | 0.18 |
| Market Cap | 2.98M |
| Revenue (ttm) | 877K |
| Net Income (ttm) | -69.97M |
| EPS (ttm) | -5.09 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.12 |
| Analyst | Hold |
| Ask | 0.2 |
| Volume | 22,062,730 |
| Avg. Volume (20D) | 15,647,530 |
| Open | 0.22 |
| Previous Close | 0.18 |
| Day's Range | 0.18 - 0.22 |
| 52-Week Range | 0.02 - 8.95 |
| Beta | 2.07 |
About AFMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AFMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AFMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Affimed N.V. is scheduled to release its earnings on Jun 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-2.99%
AFMD stock has given up its prior loss. Affimed sh...
Unlock content with
Pro Subscription
1 month ago
-2.99%
Affimed shares are trading lower after the company announced it received a Nasdaq delisting notice. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and cut its price target from $11 to $0.1.
2 months ago · https://www.marketscreener.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual MeetingAn exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improv...